Identifying the clinical indicator for surgical intervention in medication-related osteonecrosis of the jaw [0.03%]
与颌骨药物相关性坏死的手术干预临床指征的研究
Yoshiaki Tadokoro,Takumi Hasegawa,Daisuke Takeda et al.
Yoshiaki Tadokoro et al.
Introduction: Surgery has increasingly been reported as an effective treatment for medication-related osteonecrosis of the jaw (MRONJ), but concrete intervention criteria are lacking. On computed tomography (CT) images, t...
Response to the letter regarding "Postoperative risks of type 2 diabetes in elderly hip fracture patients: a propensity score-matched study" [0.03%]
关于“老年髋部骨折患者2型糖尿病术后风险:倾向性评分匹配研究”的回信
Yu Mori,Kunio Tarasawa,Hidetatsu Tanaka et al.
Yu Mori et al.
Response to the letter regarding "One-year bone mineral density gains with anti-osteoporotic medications and clinical factors associated with non-BMD gainers" [0.03%]
关于“抗骨质疏松药物一年的骨密度获益及非骨密度获益者的临床特征”的回信
Seol A Jang,Seok-Jae Heo,Su Jin Kwon et al.
Seol A Jang et al.
Association between femoral localized cortical thickening ("beaking" or "flaring") and bisphosphonate duration in glucocorticoid-induced osteoporosis [0.03%]
糖皮质激素所致骨质疏松患者股骨局部皮质增厚（“鸟嘴”或“喇叭形”）与双膦酸盐使用时间的相关性研究
Yudai Yano,Sachiko Kawasaki,Takaaki Kosugi et al.
Yudai Yano et al.
Introduction: Glucocorticoid-induced osteoporosis (GIOP) is the most common form of secondary osteoporosis, and bisphosphonates (BPs) are widely used for treatment. Localized cortical thickening (LCT, "beaking" or "flarin...
Fracture risk prediction, treatment thresholds, and the role of bone mineral density: a comparative analysis of FRAX and SHAFRE [0.03%]
骨折风险预测、治疗门槛及骨密度的作用：FRAX和SHAFRE的比较分析
Anna Nordström,Marcel Ballin,Viktor Ahlqvist et al.
Anna Nordström et al.
Introduction: Accurate prediction of fracture risk is important for treatment decisions, yet evaluations of commonly used thresholds are limited, and the added value of volumetric bone mineral density (vBMD) remains uncer...
Comment on "One‑year bone mineral density gains with anti‑osteoporotic medications and clinical factors associated with non‑BMD gainers" [0.03%]
关于“抗骨质疏松药物一年骨矿物质密度获益及非骨矿物质密度受益相关临床因素”的评论
Jie Xiao,XiaoTian Li,Jiaqi Huang
Jie Xiao
Bone fragility and atypical femoral fractures in SLE: role of disease activity, infection, and treatment [0.03%]
系统性红斑狼疮患者的骨质疏松与股骨不典型骨折：疾病活动、感染和治疗的作用
Hiroe Sato,Naoki Kondo,Tomoya Watarai et al.
Hiroe Sato et al.
Introduction: To determine the incidence and risk factors of fragility fractures and atypical femoral fracture (AFF)-related events in patients with systemic lupus erythematosus (SLE) receiving long-term glucocorticoid (G...